Bellerophon Therapeutics (BLPH) Scheduled to Post Quarterly Earnings on Friday

Bellerophon Therapeutics (NASDAQ:BLPH) will announce its earnings results on Friday, March 29th.

Bellerophon Therapeutics Stock Performance

NASDAQ:BLPH opened at $0.06 on Thursday. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $12.58. The stock has a market cap of $694,847.45, a price-to-earnings ratio of -0.07 and a beta of 0.67. The business has a fifty day moving average of $0.06 and a 200-day moving average of $0.11.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Bellerophon Therapeutics in a research note on Thursday, March 21st. They issued a “hold” rating for the company.

Institutional Investors Weigh In On Bellerophon Therapeutics

Several hedge funds have recently modified their holdings of BLPH. BlackRock Inc. lifted its stake in Bellerophon Therapeutics by 34.8% in the 2nd quarter. BlackRock Inc. now owns 129,876 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 33,527 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in Bellerophon Therapeutics in the 1st quarter worth about $7,338,000. State Street Corp lifted its stake in Bellerophon Therapeutics by 41.3% in the 1st quarter. State Street Corp now owns 30,127 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 8,800 shares in the last quarter. Geode Capital Management LLC lifted its stake in Bellerophon Therapeutics by 49.0% in the 1st quarter. Geode Capital Management LLC now owns 95,656 shares of the biotechnology company’s stock worth $755,000 after acquiring an additional 31,460 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Bellerophon Therapeutics in the 1st quarter worth about $107,000. 10.61% of the stock is owned by hedge funds and other institutional investors.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.